8:45 |
296 |
London |
Age, Tumor Grade, and MKI Are Independently Predictive of Outcome in Neuroblastoma |
9:00 |
297 |
Hiyama |
Evaluation of Heterogeneous Subgroups in Human Neuroblastoma for Clinically Relevant Risk Stratification |
9:15 |
298 |
Berthold |
Children with Metastatic Neuroblastoma between 12 and 18 Months of Age May Represent “Biological Stage 4S” |
9:30 |
299 |
Haber |
Expression of Multidrug Transporter MRP4/ABCC4 Is a Powerful Marker of Poor Prognosis in Neuroblastoma |
9:45 |
300 |
Abe |
The CpG Island Methylator Phenotype Is a Strong and Reproducible Prognostic Marker for Neuroblastoma Cases, Including Those without N-myc Amplification |
10:00 |
Break |
|
|
10:15 |
301 |
Veal |
Clinical Pharmacology of 13-cis-Retinoic Acid in Neuroblastoma A UKCCSG Pharmacology Working Group Study |
10:30 |
302 |
Villablanca |
Childrens Oncology Group Protocol ANBL0321: A Phase II Study of 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma |
10:45 |
303 |
Cheung |
FcγRIIa Polymorphism Determines Outcome Following Immunotherapy of Neuroblastoma with Anti-GD2 Antibody and GM-CSF |
11:00 |
304 |
Kushner |
Anti-GD2 Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Primary Refractory Neuroblastoma (NB) in Bone Marrow (BM) |
11:15 |
305 |
George |
Reversal of Promoter-Specific DNA Methylation in Children with Relapsed Neuroblastoma and Other Solid Tumors Treated with the Demethylating Agent, Decitabine: A Children's Oncology Group Study |
11:30 |
306 |
Matthay |
131I-Metaiodobenzylguanidine (131I-MIBG) Double Infusion with Autologous Stem Cell Transplant (ASCT) for Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study |
